Weixiang Zhong
- Oncology top 10%
- Colorectal Cancer Treatments and Studies 7
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 3
- Dermatology top 10%
- Cancer and Skin Lesions 3
-
- Cancer Genomics and Diagnostics 3
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 4
-
- Lung Cancer Treatments and Mutations 3
-
- Radiomics and Machine Learning in Medical Imaging 3
- Cited by
- OncologyImmunologyHepatology
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Weixiang Zhong
44 papers receiving 625 citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 284
- Immunology 162
- Hepatology 49
- Dermatology 50
- Cancer Research 65
Countries citing papers authored by Weixiang Zhong
This map shows the geographic impact of Weixiang Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixiang Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixiang Zhong more than expected).
Fields of papers citing papers by Weixiang Zhong
This network shows the impact of papers produced by Weixiang Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixiang Zhong. The network helps show where Weixiang Zhong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weixiang Zhong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 5 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 25 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 2 | |
| 11 | 2023 | 1 | |
| 12 | Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapybreakdown → | 2021 | 225 |
| 13 | 2021 | 14 | |
| 14 | 2021 | 3 | |
| 15 | 2020 | 2 | |
| 16 | 2020 | 10 | |
| 17 | 2018 | 10 | |
| 18 | 2018 | 16 | |
| 19 | 2018 | 28 | |
| 20 | 2018 | 1 |
About Weixiang Zhong
Weixiang Zhong is a scholar working on Oncology, Hepatology and Pathology and Forensic Medicine, having authored 49 papers that have together received 632 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Cancer Genomics and Diagnostics (3 papers), Lung Cancer Treatments and Mutations (3 papers), Radiomics and Machine Learning in Medical Imaging (3 papers), CAR-T cell therapy research (3 papers) and Cancer and Skin Lesions (3 papers). The work is most often cited by research in Oncology (284 citations), Immunology (162 citations) and Hepatology (49 citations). Weixiang Zhong has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Weiqin Jiang, Yinjun He, Wenguang He, Guosheng Wu, Xile Zhou, Yongfeng Ding, Hanju Hua, Qinsong Sheng, Yimin Lu and Lu Qi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Neuroscience.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.